Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Mongardon, Nicolas ^a,b   Max, Adeline ^a,b   Bouglé, Adrien ^a,b   Pène, Frédéric ^a,b,c   Lemiale, Virginie ^a,b   Charpentier, Julien ^a,b   Cariou, Alain ^a,b   Chiche, Jean Daniel ^a,b,c   Bedos, Jean Pierre ^d   Mira, Jean Paul ^a,b,c  

^a Assistance Publique des Hôpitaux de Paris ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ACUTE RESPIRATORY FAILURE; ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL STRAIN; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORTICOSTEROID THERAPY; DATA BASE; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SEPTIC SHOCK; SEX; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ACUTE KIDNEY INJURY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; DRUG EFFECTS; LENGTH OF STAY; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA, PNEUMOCOCCAL; RESPIRATORY INSUFFICIENCY; RISK FACTOR; SEASON; SHOCK, SEPTIC; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SEASONS; SHOCK, SEPTIC; STREPTOCOCCUS PNEUMONIAE;

EID: 84864945655     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11471     Document Type: Article

References (58)

1. Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis 2006, 42:e1-5. 10.1086/498745, 16323082.
2. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001, 285:1729-1735. 10.1001/jama.285.13.1729, 11277827.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
4. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007, 86:103-111.
5. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010, 36:222-231. 10.1007/s00134-009-1738-3, 2826633, 20069275.
6. Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010, 138:279-283. 10.1378/chest.09-2702, 20382718.
7. File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141. 10.3810/pgm.2010.03.2130, 20203464.
8. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620. 10.1007/s00134-009-1730-y, 19953222.
9. Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, Beaucaire G. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999, 25:198-206. 10.1007/s001340050816, 10193548.
10. Moine P, Vercken JB, Chevret S, Gajdos P. Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU. Scand J Infect Dis 1995, 27:201-206. 10.3109/00365549509019009, 8539541.
11. Wunderink RG. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2009, 30:146-153. 10.1055/s-0029-1202933, 19296414.
12. Van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374:1543-1556. 10.1016/S0140-6736(09)61114-4, 19880020.
13. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
14. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998, 158:1102-1108.
15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009, 136:e28. 10.1378/chest.09-2267, 20162763.
16. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
17. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-212. 10.1186/cc2872, 522841, 15312219.
18. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 1996, 276:802-810. 10.1001/jama.1996.03540100046027, 8769590.
19. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.1993.03510240069035, 8254858.
20. Antibiogram Committee of the French Society for Microbiology. , http://www.sfm.asso.fr/
21. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000, 342:681-689. 10.1056/NEJM200003093421002, 10706897.
22. Mahmood K, Eldeirawi K, Wahidi MM. Association of gender with outcomes in critically ill patients. Crit Care 2012, 16:R92. 10.1186/cc11355, 22617003.
23. Angele MK, Pratschke S, Chaudry IH. Does gender influence outcomes in critically ill patients?. Crit Care 2012, 16:129. 10.1186/CC11365, 22694926.
24. Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Sole-Violan J, De Mendoza D, Rello J. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009, 35:430-438. 10.1007/s00134-008-1363-6, 19066850.
25. Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Diaz V, Verdaguer R, Dorca J, Manresa F, Gudiol F. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008, 32:733-739. 10.1183/09031936.00128107, 18508820.
26. Marrie TJ, Low DE, De Carolis E. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J 2003, 10:368-374.
27. Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T, Ramirez J. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 2008, 133:618-624. 10.1378/chest.07-1322, 18198264.
28. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
29. Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Linares J, Gudiol F, Carratala J. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 2010, 65:77-81. 10.1136/thx.2009.123612, 19996337.
30. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005, 33:952-961. 10.1097/01.CCM.0000162381.24074.D7, 15891319.
31. Angus DC. Drotrecogin alfa (activated) ... a sad final fizzle to a roller-coaster party. Crit Care 2012, 16:107. 10.1186/cc11152, 22309988.
32. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011, 183:1561-1568. 10.1164/rccm.201007-1167OC, 21297074.
33. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.
34. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010, 181:975-982. 10.1164/rccm.200905-0808OC, 20133929.
35. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124. 10.1056/NEJMoa071366, 18184957.
36. Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009, 63:1025-1033. 10.1093/jac/dkp088, 19293196.
37. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395. 10.1086/367541, 12567294.
38. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842. 10.1001/archinte.161.15.1837, 11493124.
39. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, Tremblay J. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11:589-593.
40. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444. 10.1164/rccm.200311-1578OC, 15184200.
41. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498. 10.1097/01.CCM.0000266755.75844.05, 17452932.
42. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-159. 10.1183/09031936.00054108, 18768577.
43. Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007, 26:447-451. 10.1007/s10096-007-0307-3, 17534677.
44. Dwyer R, Ortqvist A, Aufwerber E, Henriques Normark B, Marrie TJ, Mufson MA, Torres A, Woodhead MA, Alenius M, Kalin M. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25:518-521. 10.1007/s10096-006-0183-2, 16896822.
45. Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderias L, Cabello FJ, Tabara J, Hernandez-Flix S, Martinez-Sanchis A, Torres A. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006, 27:1010-1019.
46. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000, 22:872-878. 10.1016/S0149-2918(00)80059-4, 10945513.
47. Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S, Almanasreh N, Goldberg E, Cauda R, Frank U, Leibovici L. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007, 30:525-531. 10.1183/09031936.00031007, 17537772.
48. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005, 24:688-690. 10.1007/s10096-005-0018-6, 16215712.
49. Dowell SF, Whitney CG, Wright C, Rose CE, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis 2003, 9:573-579. 10.3201/eid0905.020556, 12737741.
50. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, Schaffner W, Craig AS, Griffin MR. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med 2005, 118:285-291. 10.1016/j.amjmed.2004.09.016, 15745727.
51. Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill 2008, pii: 19035.
52. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480. 10.1056/NEJM199508243330802, 7623879.
53. Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, Espana PP, Rello J, Torres A. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004, 38:787-798. 10.1086/381886, 14999620.
54. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
55. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, Lim TK. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009, 64:598-603. 10.1136/thx.2009.113795, 19386583.
56. Lujan M, Gallego M, Belmonte Y, Fontanals D, Valles J, Lisboa T, Rello J. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010, 36:1073-1079. 10.1183/09031936.00176309, 20150202.
57. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 2008, 12(Suppl 6):S5. 10.1186/cc7028, 2607115, 19105798.
58. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:31-44. 10.1016/S1473-3099(08)70261-5, 19036641.